BRIEF-Valeant Pharmaceuticals restates Q4 results after review
April 29, 2016 at 08:32 AM EDT
* Restates q4 results after review; now says q4 gaap loss per share $1.12; co on march 15 reported q4 gaap loss per share of $0.98
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.